'Prior chemotherapy' diaporamas de présentation

Lester J Peters MD

915 views • 76 slides

SABCS 2011 Metastatic Breast Cancer Shiuh-Wen Luoh MD PhD Clinical Associate Professor

SABCS 2011 Metastatic Breast Cancer Shiuh-Wen Luoh MD PhD Clinical Associate Professor Comprehensive Breast Cancer Clinic Hematology and Medical Oncology Knight Cancer Institute, OHSU Portland VA Medical Center. BOLERO-2 SWOG-0226.

799 views • 60 slides

Critical Concepts in the Use of Combination Chemotherapy With Targeted Agents

Critical Concepts in the Use of Combination Chemotherapy With Targeted Agents. Lee M. Ellis, MD. The University of Texas MD Anderson Cancer Center. Combination Chemotherapy + Targeted Therapy in GI Cancers After all, I only have 20 minutes. Scientific rationale and biology

487 views • 34 slides

Paolo G. Casali, John Zalcberg , Jaap Verweij , Axel Le Cesne ,

LONG-TERM ANALYSIS OF A PHASE III RANDOMIZED, INTERGROUP, INTERNATIONAL TRIAL ASSESSING THE CLINICAL ACTIVITY OF IMATINIB AT TWO DOSE LEVELS IN PATIENTS WITH UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMORS (GIST).

420 views • 28 slides

BR.21 schema

397 views • 24 slides

Niall C. Tebbutt

Niall C. Tebbutt. International randomised phase III study of capecitabine, bevacizumab, and mitomycin C in first-line treatment of metastatic colorectal cancer: Final results of AGITG MAX study. The MAX study: final results.

288 views • 21 slides

APML

776 views • 20 slides

Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design

364 views • 14 slides

Kochenderfer JN et al. Proc ASH 2013;Abstract 168.

Effective Treatment o f Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma with Autologous T Cells Genetically-Engineered to Express an Anti-CD19 Chimeric Antigen Receptor. Kochenderfer JN et al. Proc ASH 2013;Abstract 168. Background.

250 views • 12 slides

AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4)

AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4). A randomized trial evaluating cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Strata: Platinum-free-interval 6-12 vs > 12 months 1st line platinum based chx: yes vs no. Cytoreductive surgery. R A N

460 views • 7 slides